Capricor Therapeutics is trading 8.93% down at $6.78 after an FDA advisory panel voted 9-3 against deramiocel’s effectiveness for Duchenne muscular dystrophy cardiomyopathy.
- The August 17 earnings update reported a $40.7 million second-quarter net loss, no revenue, and approximately 12 months of cash runway.
- Shares closed at $7.45 on August 17 after rising 12.03%, following a 57.96% gain on August 14.
- A newly publicized securities-fraud lawsuit adds pressure; broader risk-off sentiment may be a headwind, with Nasdaq down 1.49%. Primary catalyst remains company-specific regulatory and financial uncertainty.